Peer Review History

Original SubmissionFebruary 15, 2024
Decision Letter - Donovan Anthony McGrowder, Editor

PONE-D-24-05709

Metabolic Syndrome Predictive Modeling in Bangladesh applying Machine Learning Approach

PLOS ONE

Dear Dr. Hossain,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 22 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Donovan Anthony McGrowder, PhD., MA., MSc

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please note that PLOS ONE has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, all author-generated code must be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.

3. We note that you have indicated that there are restrictions to data sharing for this study. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

Before we proceed with your manuscript, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see

https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.

We will update your Data Availability statement on your behalf to reflect the information you provide.

4. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

6. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

7. We note that Figure 1 in your submission contain map/satellite images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (a) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (b) remove the figures from your submission:

a. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license.  

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

Additional Editor Comments:

Dear Dr. Hossain,

Your manuscript “Metabolic Syndrome Predictive Modeling in Bangladesh applying Machine Learning Approach” has been assessed by our reviewers. They have raised a number of points which we believe would improve the manuscript and may allow a revised version to be published in PLOS ONE. Their reports, together with any other comments given are below.

If you are able to fully address these points, we would encourage you to submit a revised manuscript to PLOS ONE by the date given below.

 Best regards,

Dr. Donovan McGrowder

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Abstract:

- The abstract should clearly state the main objectives, methodology, key results, conclusions and limitations of the study. Currently it only summarizes the background.

- Include the key risk factors identified, prevalence of MetS found, and main ML model utilized in the results.

Introduction:

- Expand more on the rationale for identifying risk factors and predicting MetS prevalence in the Bangladeshi population specifically.

- after ''and working in irregular shifts[7].'' discuss the role in particular of obstructive sleep apnea. cite doi:10.3390/life13030702.

- Provide more background on MetS diagnostic criteria and associated health risks to establish significance.

Methods:

- Describe the National STEPS Survey sampling methodology, data collection procedures, and variables obtained in more detail.

- Explain how MetS was defined - which diagnostic criteria used.

- Specify why certain variables were categorized and encoding approaches for ML models.

- State specific ML models, parameters, evaluation metrics, and statistical analysis done.

Results:

- Focus this section only on key results - prevalence, risk factors, model performance. Remove general discussion.

- Include quantitative performance metrics for each ML model - precision, recall, ROC, etc.

Discussion:

- Limitations should note small subset of survey data used, exclusion of potentially relevant variables like lipids. cite doi:10.1016/j.compbiomed.

- Discussion of inflammation markers and future studies seems speculative without any results presented. Would remove.

- Avoid overstating conclusions on predictive capabilities of models until externally validated.

Reviewer #2: Dear authors,

I have now completed the review of the manuscript titled "Metabolic Syndrome Predictive Modeling in Bangladesh applying Machine Learning Approach".

The author aims to predict the prevalence of Metabolic Syndrome (MetS) in Bangladesh using various machine learning algorithms. The study analyzes data from 8185 participants, identifying key risk factors for MetS and assessing the performance of different models in predicting the condition.

The manuscript is interesting and, in general, fairly well-written.

I have some suggestions to further improve the quality of the manuscript.

I would like to suggest that the authors address these limitations in the article, either by discussing them in the limitations section or, where feasible, by making the appropriate revisions:

1. It's crucial to assess how well the models generalize to unseen data. Cross-validation techniques and external validation on datasets from different populations could enhance the robustness of the findings.

2. The study could benefit from a direct comparison with existing predictive models for MetS to highlight its contributions or improvements.

3. While the study employs feature selection techniques, further exploration into dimensionality reduction methods could improve model performance and interpretability.

4. The exclusion of certain variables deemed insignificant could potentially overlook complex interactions between features that contribute to MetS. A more detailed analysis or justification for the exclusion of these variables might provide deeper insights.

5. The practical applicability of the models in clinical settings is not extensively discussed. Future work could focus on how these models can be integrated into healthcare systems for early detection and intervention strategies.

6. Mention breifly deep learning methods article and add in the reference. For example: "An Adaptive Ensemble Deep Learning Framework for Reliable Detection of Pandemic Patients", "Deep Learning Network Selection and Optimized Information Fusion for Enhanced COVID-19 Detection". Deep learning could offer insight into the future research direction.

Thank you for your valuable contributions to our field of research. I look forward to receiving the revised manuscript.

Reviewer #3: In this study, Hossain et al. perform machine learning to identify risk factors for metabolic syndrome. The topic is interesting, and data support the authors’ conclusions. The story is clear; however, the method section is incomplete. The authors write general information of procedures, such as what sensitivity is or how specificity is calculated. This basic and general information is not necessary. The authors should write procedures the authors performed in this study, but no information is provided in this manuscript, which is not appropriate. The authors should provide more detailed information of procedures, such as R and its version, packages, parameters used in analysis, etc.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Antonino

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Reviewer 1:

Reviewer comments Responses

The abstract should clearly state the main objectives, methodology, key results, conclusions, and limitations of the study. Currently it only summarizes the background. We appreciate your feedback. The primary goals, methodology, important findings, conclusions, and limitations of the study have all been spelled out in detail in the abstract.

Include the key risk factors identified, prevalence of MetS found, and main ML model utilized in the results. Thank you for your recommendations. The major machine learning model used in the results, the prevalence of MetS, and the key risk variables revealed have all been presented in the "abstract".

Expand more on the rationale for identifying risk factors and predicting MetS prevalence in the Bangladeshi population specifically. We appreciate your recommendations. The reasoning behind determining risk variables and forecasting the incidence of MetS in the Bangladeshi population in particular is covered in greater detail in the "Introduction section" of our publication.

after ‘and working in irregular shifts [7].'discuss the role in particular of obstructive sleep apnea. cite doi:10.3390/life13030702. Thanks for your suggestions. According to this research doi:10.3390/life13030702, we have addressed the role of obstructive sleep apnea specifically in the "Introduction section."

Provide more background on MetS diagnostic criteria and associated health risks to establish significance. We appreciate your recommendations. To establish significance, we have included further background information on MetS diagnostic criteria and related health hazards in the "Introduction section" of our publication.

Describe the National STEPS Survey sampling methodology, data collection procedures, and variables obtained in more detail. Thank you for your recommendations. More information on the National STEPS Survey sampling methodology, data collection techniques, and variables gathered may be found in the section titled "Data Source in the Methodology section."

Explain how MetS was defined - which diagnostic criteria used Thanks for your suggestionsThe definition of MetS and the diagnostic criteria that were applied are covered in the section on "diagnostic criteria in the Methodology section."

Specify why certain variables were categorized and encoding approaches for ML models We have explained why specific variables were categorized and encoding methodologies for ML models in the section "Variable importance and key risk factors of metabolic syndrome in the Results and analysis section."

State specific ML models, parameters, evaluation metrics, and statistical analysis done Thanks for your suggestions. Certain machine learning models, parameters, assessment metrics, and statistical analysis have been specified in the "Results and analysis" portion of Tables 2, 3, and 4.

Focus this section only on key results - prevalence, risk factors, model performance. Remove general discussion We appreciate your recommendations. We only included the most important findings—prevalence, risk variables, and model performance—in the "Results and analysis" section.

Include quantitative performance metrics for each ML model - precision, recall, ROC, etc. Thank you for your tremendous recommendations. We incorporated numerical performance indicators, such as precision, recall, ROC, and so on, for every machine learning model in our manuscript's "Results and analysis section in Table 4."

Limitations should note small subset of survey data used, exclusion of potentially relevant variables like lipids. cite doi:10.1016/j.compbiomed We appreciate your recommendations. We have mentioned in the "Limitations Section" that a tiny subset of survey data was utilized, that potentially relevant factors like lipids were excluded, and that we cited this article doi:10.1016/j.compbiomed.

Discussion of inflammation markers and future studies seems speculative without any results presented. Would remove. We appreciate your insightful recommendations. The part about future research and signs of inflammation has been removed.

Avoid overstating conclusions on predictive capabilities of models until externally validated Thanks for your valuable suggestions. This has been deleted from the "Conclusion section."

Reviewer #2

Reviewer comments Responses

It's crucial to assess how well the models generalize to unseen data. Cross-validation techniques and external validation on datasets from different populations could enhance the robustness of the findings. Your insightful recommendations are appreciated. After examining datasets from various populations, we have conducted cross-validation and external validation on our models and found that they perform well.

The study could benefit from a direct comparison with existing predictive models for MetS to highlight its contributions or improvements We appreciate your insightful recommendations. There are no current MetS prediction models available that we can compare our model to from the standpoint of the Bangladeshi population. Our models showed marginally less accuracy when we compared them to the state-of-the-art models from China and Mexico.

While the study employs feature selection techniques, further exploration into dimensionality reduction methods could improve model performance and interpretability. Thanks for your valuable suggestions. Although we have looked into dimensionality reduction techniques, our model's performance remains unchanged.

The exclusion of certain variables deemed insignificant could potentially overlook complex interactions between features that contribute to MetS. A more detailed analysis or justification for the exclusion of these variables might provide deeper insights. Table 5 in the "Results and analysis section" illustrates how these variables lower the models' overall performance. Because of this, we have decided to eliminate these factors from our study because they don't really matter for our findings. We think more research is necessary to ignore the intricate relationships between the characteristics that cause MetS.

The practical applicability of the models in clinical settings is not extensively discussed. Future work could focus on how these models can be integrated into healthcare systems for early detection and intervention strategies We appreciate your recommendations. The "Discussion and recommendations section" of our publication contains a brief discussion of the models' usefulness in clinical settings. To further understand how machine learning models might be incorporated into Bangladeshi healthcare systems for early detection and intervention measures, we think more research is needed.

Mention briefly deep learning methods article and add in the reference. For example: "An Adaptive Ensemble Deep Learning Framework for Reliable Detection of Pandemic Patients", "Deep Learning Network Selection and Optimized Information Fusion for Enhanced COVID-19 Detection". Deep learning could offer insight into the future research direction. Thanks for your important suggestions. In the "Related work section" of our manuscript, we have included a brief reference of an article on deep learning that may provide some light on potential future study directions.

Reviewer #3

Reviewer comments Responses

This basic and general information is not necessary. The authors should write procedures the authors performed in this study, but no information is provided in this manuscript, which is not appropriate. The authors should provide more detailed information of procedures, such as R and its version, packages, parameters used in analysis, etc. Thanks for your suggestions. We removed the general discussion as possible. We included the author’s contribution in this manuscript. We provided detailed information of procedures. We used SPSS Python instead of R. We included its version, libraries and parameter used in analysis.

Attachments
Attachment
Submitted filename: Response to Reviewer.pdf
Decision Letter - Aleksandra Klisic, Editor

Metabolic Syndrome Predictive Modeling in Bangladesh applying Machine Learning Approach

PONE-D-24-05709R1

Dear Dr. Hossain,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Aleksandra Klisic

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript Is improved and the Authors performed all the revisions required. I can suggest tò accept.

Reviewer #2: All comments were addressed. I declare no further comments to be included. Thank you for considering my opinion.

Reviewer #3: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: None

Reviewer #2: No

Reviewer #3: No

**********

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .